SE448678B - Farmaceutisk beredning som vesentligen bestar av eikosapentaensyra eller derivat derav - Google Patents

Farmaceutisk beredning som vesentligen bestar av eikosapentaensyra eller derivat derav

Info

Publication number
SE448678B
SE448678B SE7904570A SE7904570A SE448678B SE 448678 B SE448678 B SE 448678B SE 7904570 A SE7904570 A SE 7904570A SE 7904570 A SE7904570 A SE 7904570A SE 448678 B SE448678 B SE 448678B
Authority
SE
Sweden
Prior art keywords
acid
pharmaceutically acceptable
eicosapentaenoic acid
pharmaceutical preparation
salt
Prior art date
Application number
SE7904570A
Other languages
English (en)
Swedish (sv)
Other versions
SE7904570L (sv
Inventor
H O Bang
J Dyerberg
J R Vane
S E Moncada
Original Assignee
Mochida Pharm Co Ltd
Nippon Suisan Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2357578A external-priority patent/GB1604554A/en
Application filed by Mochida Pharm Co Ltd, Nippon Suisan Kaisha Ltd filed Critical Mochida Pharm Co Ltd
Publication of SE7904570L publication Critical patent/SE7904570L/
Publication of SE448678B publication Critical patent/SE448678B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C15/00—Butter; Butter preparations; Making thereof
    • A23C15/12—Butter preparations
    • A23C15/126—Butter containing a minority of vegetable oils; Enrichment of butter with fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE7904570A 1978-05-26 1979-05-25 Farmaceutisk beredning som vesentligen bestar av eikosapentaensyra eller derivat derav SE448678B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2357478 1978-05-26
GB2357578A GB1604554A (en) 1978-05-26 1978-05-26 Pharmaceutical and food formulations

Publications (2)

Publication Number Publication Date
SE7904570L SE7904570L (sv) 1979-11-27
SE448678B true SE448678B (sv) 1987-03-16

Family

ID=26256599

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7904570A SE448678B (sv) 1978-05-26 1979-05-25 Farmaceutisk beredning som vesentligen bestar av eikosapentaensyra eller derivat derav

Country Status (13)

Country Link
JP (1) JPS5515444A (enrdf_load_stackoverflow)
AU (1) AU527784B2 (enrdf_load_stackoverflow)
CA (1) CA1151068A (enrdf_load_stackoverflow)
CH (1) CH644267A5 (enrdf_load_stackoverflow)
DE (1) DE2831507A1 (enrdf_load_stackoverflow)
ES (1) ES8104983A1 (enrdf_load_stackoverflow)
FR (1) FR2426461A1 (enrdf_load_stackoverflow)
IE (1) IE48287B1 (enrdf_load_stackoverflow)
IL (1) IL55227A (enrdf_load_stackoverflow)
IT (1) IT1116505B (enrdf_load_stackoverflow)
NL (1) NL191332C (enrdf_load_stackoverflow)
NZ (1) NZ187908A (enrdf_load_stackoverflow)
SE (1) SE448678B (enrdf_load_stackoverflow)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
JPS59172416A (ja) * 1983-03-18 1984-09-29 Terumo Corp 脂肪輸液
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS60132916A (ja) * 1983-12-21 1985-07-16 Nisshin Oil Mills Ltd:The 血栓症予防食品または医薬品
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
JPH0748991B2 (ja) * 1984-08-29 1995-05-31 日本油脂株式会社 経管栄養組成物
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
NL9401743A (nl) * 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
DE19503993A1 (de) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
DE10056351A1 (de) * 2000-11-14 2002-05-29 Weylandt Karsten Henrich Pharmazeutisches Präparat
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
NZ595852A (en) 2009-04-29 2014-07-25 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
PT4338805T (pt) 2012-06-29 2025-09-02 Amarin Pharmaceuticals Ie Ltd Éster etílico do ácido eicosapentanoico para utilização na redução do risco de enfarte do miocárdio não fatal num indivíduo em terapia com estatina
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
SG11201505460WA (en) 2013-02-06 2015-08-28 Agency Science Tech & Res Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20230038594A (ko) 2018-09-24 2023-03-20 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE319677B (enrdf_load_stackoverflow) * 1965-03-27 1970-01-19 Sumitomo Chemical Co
FR2097036A1 (en) * 1970-07-29 1972-03-03 Sopharga Lab Lipids contg fatty acids - for treatment of atheroslerosis
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
JPS6257605A (ja) * 1985-09-05 1987-03-13 Kaizuka Kazutoshi 多元素鉱物からの有効成分抽出方法

Also Published As

Publication number Publication date
SE7904570L (sv) 1979-11-27
IL55227A0 (en) 1978-09-29
IT7947717A0 (it) 1979-01-19
CA1151068A (en) 1983-08-02
FR2426461A1 (fr) 1979-12-21
AU3808478A (en) 1980-01-17
IL55227A (en) 1982-12-31
NL191332C (nl) 1995-06-01
ES480921A0 (es) 1981-05-16
CH644267A5 (en) 1984-07-31
IE791023L (en) 1979-11-26
ES8104983A1 (es) 1981-05-16
DE2831507A1 (de) 1979-11-29
JPS5515444A (en) 1980-02-02
FR2426461B1 (enrdf_load_stackoverflow) 1983-02-11
NL191332B (nl) 1995-01-02
IT1116505B (it) 1986-02-10
AU527784B2 (en) 1983-03-24
DE2831507C2 (enrdf_load_stackoverflow) 1989-07-13
NL7904144A (nl) 1979-11-28
IE48287B1 (en) 1984-11-28
NZ187908A (en) 1984-05-31

Similar Documents

Publication Publication Date Title
SE448678B (sv) Farmaceutisk beredning som vesentligen bestar av eikosapentaensyra eller derivat derav
GB2033745A (en) Fatty acid and derivatives thereof in treatment or prophylaxis of thrombo-embolic conditions
Sanders et al. The influence of different types of ω 3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers
JP2662728B2 (ja) オメガ―３脂肪酸エステルの速効性静脈内エマルジョン
Leaf et al. Prevention of cardiac sudden death by N‐3 fatty acids: a review of the evidence
Mehta et al. Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease: effects on indices of platelet and neutrophil function and exercise performance
KR0126286B1 (ko) 지방산 조성물
Vergroesen Dietary fat and cardiovascular disease: possible modes of action of linoleic acid
Gudbjarnason Dynamics of n‐3 and n‐6 fatty acids in phospholipids of heart muscle
CA1280370C (en) PHARMACEUTICAL AND DIETARY COMPOSITION CONTAINING .alpha.-LINOLEIC ACID
Sanders Essential and trans-fatty acids in nutrition
US4058594A (en) Immuno-suppressive agents
US3993775A (en) Immuno-suppressive agents
JP2000506840A (ja) アレルギー性応答を弱毒化するための複合リノール酸
JPH0349890B2 (enrdf_load_stackoverflow)
Holub Dietary fish oils containing eicosapentaenoic acid and the prevention of atherosclerosis and thrombosis
GB1604554A (en) Pharmaceutical and food formulations
BALLARD-BARBASH et al. Marine fish oils: role in prevention of coronary artery disease
JPS6257605B2 (enrdf_load_stackoverflow)
US9808437B2 (en) Monounsaturated fatty acid compositions and use for treating atherosclerosis
Goodnight Jr THE ANTITHROMBOTIC EFFECTS OF FISH OIL¹
JPH04169525A (ja) 血清脂質改善機能を有する組成物
Zeller et al. Fish oil: effectiveness as a dietary supplement in the prevention of heart disease
JP3177686B2 (ja) 月経困難症予防または治療剤と月経困難症予防機能性食品
AU2005244483B2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7904570-4

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7904570-4

Format of ref document f/p: F